NuCana PLC (NCNA)
| Market Cap | 109.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.97M |
| Shares Out | 52.16M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $2.12 |
| Previous Close | $2.14 |
| Change ($) | -0.02 |
| Change (%) | -0.93% |
| Day's Open | 2.15 |
| Day's Range | 2.08 - 2.15 |
| Day's Volume | 393,580 |
| 52-Week Range | 2.03 - 7.83 |
Presented Encouraging Clinical Data at ASCO-GI and AACR
EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one...
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2...
Presented Encouraging Clinical Data for NUC-3373 and NUC-7738
Find out what led to the biotech industry's biggest gains.
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy
NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors
Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed
Completed Successful $ 8 0 million Public Offering
EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...
EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present a...
NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering
NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)
EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...
EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...
EDINBURGH, United Kingdom, Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, ann...
EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinic...
NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As of late, it has definitely been a great time to be an investor of NuCana
Top Ranked Momentum Stocks to Buy for May 28th
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic
EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary paus...
EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-...
EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today ...
Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population
EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued a...
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin
NUC-3373: Favorable Pharmacokinetic Profile Demonstrated
Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin
As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).
EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present...
EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host on...
Numerous Clinical Data Announcements and Study Initiations Expected in 2019
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
Shares of NuCana Plc fell 21% on Tuesday after the company announced it had suspended the enrollment of new patients in a late-stage trial of a pancreatic cancer drug.
Imbalances in Prognostic Factors May Have Impacted Analysis
Falling Knives are companies whose share prices have fallen more than 59% over the past year, generating the interest of investors as they can make huge gains if they bounce back.
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
NCNA’s ProTide technology has been used to develop drugs like Sovaldi and Genvoya.
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian can... [Read more...]
| Industry Biotechnology | IPO Date Sep 28, 2017 |
| CEO Hugh Griffith | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol NCNA |
Analyst Forecasts
According to 8 analysts, the average rating for NuCana stock is "Strong Buy." The 12-month stock price forecast is 1,144.93, which is an increase of 53,906.13% from the latest price.